Bethany Jackson, MD
Endocrinology, Diabetes & Metabolism · Florence, ALNPI 1750517835
Payments from drug & device makers
Across 1,473 payments — averaging $61.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$38K
- Tandem Diabetes Care, Inc.$27K
- Medtronic$3K
- Lilly USA, LLC$3K
- Sanofi-aventis U.S. LLC$2K
- Insulet Corporation$2K
- plus $15K from 46 others
What the payments were for
- Speaking & faculty fees$59,30866%
- Travel & lodging$4,5265%
- Food & beverage$26,39029%
- Education$2320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$21,850
- Ozempic$9,910
- Tresiba$9,726
- RYBELSUS$7,000
- Xultophy 100/3.6$5,675
- t-slim insulin pump$4,800
- Omnipod$1,642
- Eversense$1,308
- MINIMED 780G$1,247
- FARXIGA$619
- FreeStyle Libre 2$419
- TOUJEO$389
- t:slim X2 Insulin Pump with Control-IQ$354
- FREESTYLE LIBRE 3$154
- FreeStyle Libre$153
- SOLIQUA 100/33$147
- TWIIST$133
- DEXCOM G7 GSS (161)$125
- DEXCOM STELO GLUCOSE BIOSENSOR$125
- AREXVY$125
How this compares
$90,456 in reported general payments places this provider in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 748 | $938,083 |
| OzempicSemaglutide | 604 | $800,495 |
| JardianceEmpagliflozin | 418 | $420,666 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 294 | $289,915 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 284 | $250,840 |
| Tresiba Flextouch U-100Insulin Degludec | 272 | $224,566 |
| FarxigaDapagliflozin Propanediol | 298 | $213,992 |
| Humalog Kwikpen U-200Insulin Lispro | 40 | $194,482 |
| Xigduo XrDapaglifloz Propaned/Metformin | 184 | $184,484 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 141 | $183,289 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 136 | $169,355 |
| Tresiba Flextouch U-200Insulin Degludec | 99 | $161,484 |
| TrulicityDulaglutide | 107 | $160,592 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 225 | $132,381 |
| IsturisaOsilodrostat Phosphate | 11 | $111,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,832 | $1,126,841927 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog, Fiasp | $37,581 | $930,132739 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi, Synjardy | $1,216 | $805,212838 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,367 | $289,915294 claims |
| AstraZenecaFarxiga | $2,101 | $213,992298 claims |
| Recordati_rare_diseases_inc.Isturisa | $142 | $111,50311 claims |
| MerckJanuvia, Janumet Xr | $284 | $34,64536 claims |
| AbbVieSynthroid | $1,045 | $26,245331 claims |
| IBSA Pharma Inc.Tirosint | $484 | $10,93160 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $50 | $9,379775 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Florence
- Syed AhmedFlorence$3K
- William GarveyBirmingham$3.8M
- Neil SchaffnerOpelika$642K
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- Judson MenefeeFairhope$185K
- Amy WarrinerBirmingham$182K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.